Chromocell Therapeutics Files 8-K
Ticker: PTHS · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1919246
| Field | Detail |
|---|---|
| Company | Chromocell Therapeutics Corp (PTHS) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-disclosure, financial-reporting
TL;DR
Chromocell Therapeutics filed an 8-K on 4/9/24, updating corporate info and financial statements.
AI Summary
Chromocell Therapeutics Corporation filed an 8-K on April 9, 2024, to report other events and financial statements. The filing details the company's principal executive office located at 4400 Route 9 South, Suite 1000, Freehold, NJ 07728, and its telephone number is 732-514-2636. The company is incorporated in Delaware and operates in the Biological Products sector.
Why It Matters
This filing provides an update on Chromocell Therapeutics' corporate and financial reporting, which is essential for investors to stay informed about the company's operational status and disclosures.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Chromocell Therapeutics Corporation (company) — Registrant
- April 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 4400 Route 9 South, Suite 1000 Freehold, NJ 07728 (address) — Registrant's principal executive office
- 732-514-2636 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' for Chromocell Therapeutics Corporation.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on April 9, 2024.
In which state is Chromocell Therapeutics Corporation incorporated?
Chromocell Therapeutics Corporation is incorporated in Delaware.
What is the principal executive office address for Chromocell Therapeutics Corporation?
The principal executive office address is 4400 Route 9 South, Suite 1000, Freehold, NJ 07728.
What is the telephone number listed for Chromocell Therapeutics Corporation?
The telephone number listed for Chromocell Therapeutics Corporation is 732-514-2636.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2024-04-09 08:30:29
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share CHRO The NYSE American LL
Filing Documents
- g084169_8k.htm (8-K) — 31KB
- g084169_ex99-1.htm (EX-99.1) — 31KB
- 0001753926-24-000691.txt ( ) — 241KB
- chro-20240409.xsd (EX-101.SCH) — 3KB
- chro-20240409_lab.xml (EX-101.LAB) — 33KB
- chro-20240409_pre.xml (EX-101.PRE) — 22KB
- g084169_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On April 9, 2024, Chromocell Therapeutics Corporation (the "Company") issued a press release containing a letter from the Company's Chief Executive Officer. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Chromocell Therapeutics Corporation, dated April 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 9, 2024 CHROMOCELL THERAPEUTICS CORPORATION By: /s/ Francis Knuettel II Name: Francis Knuettel II Title: Chief Executive Officer and Chief Financial Officer